Mesenchymal stem cells (MSCs) have shown therapeutic potential if successfully delivered to the intended site of myocardial infarction. The purpose of this pilot study was to test the feasibility of 111In oxine labelling of MSCs and single photon emission computed tomography (SPECT) imaging after intravenous administration in a porcine model of myocardial infarction. Adult farm pigs (n=2) were subjected to closed chest experimental myocardial infarction. 111In oxine labelled MSCs (1 x 10(7) to 2 x 10(7) cells) were infused intravenously, and SPECT imaging was performed initially and on days 1, 2, 7 and 14. High quality SPECT images were obtained through 2 weeks of imaging. High initial MSC localization occurred in the lungs and slow progressive accumulation occurred in the liver, spleen and bone marrow. Renal activity was mild and persistent throughout imaging. No appreciable accumulation occurred in the myocardium. It is concluded that 111In oxine radiolabelling of MSCs is feasible, and in vivo imaging with SPECT provides a non-invasive method for sequentially monitoring cell trafficking with good spatial resolution. Because intravenous administration of MSCs results in significant lung activity that obscures the assessment of myocardial cell trafficking, alternative routes of administration should be investigated for this application.
1 January 2004 in The Journal of Clinical Endocrinology & Metabolism
TSH stimulates thyrocyte metabolism, glucose transport, and glycolysis. 2-Deoxy-2-[18F]fluoro-d-glucose (FDG) is a glucose analog used in positron emission tomography (PET) to detect occult well-differentiated thyroid carcinoma. The objective of this study was to examine the effects of recombinant human TSH (rTSH) on FDG PET uptake in patients with residual or recurrent disease. Seven patients with well-differentiated thyroid carcinoma, negative 131-I scintigraphy, and biochemical evidence of residual disease were randomized and prospectively studied with FDG PET both on thyroid hormone suppression and rTSH stimulation within 1 wk. All lesions seen on the TSH suppression scans were seen on the rTSH stimulation studies. rTSH stimulation studies identified four additional lesions not seen on TSH suppression. One patient was positive on rTSH stimulation alone. The mean (2.54 ± 0.72 vs. 1.79 ± 0.88) and maximum (2.49 ± 0.95 vs. 1.74 ± 0.81) lesion to background ratios were significantly higher with rTSH stimulation, compared with TSH suppression (P = 0.02 for both). rTSH stimulation improves the detectability of occult thyroid metastases with FDG PET, compared with scans performed on TSH suppression.
To investigate the effects of intravenous contrast agents on quantitative values obtained with a combined positron emission tomographic (PET) and computed tomographic (CT) scanner by using several phantoms and a dog. Fluorine 18 fluorodeoxyglucose (FDG) was mixed with different concentrations of contrast agent with the same syringe (phantom 1), and the phantom was scanned. After image reconstruction with various attenuation maps, radioactivity concentrations were compared. Then, FDG solutions with (phantom 2) or surrounded by (phantom 3) various concentrations of contrast agent were scanned repeatedly, and radioactivity concentration was compared. Finally, PET and CT with and without contrast agent were performed in a dog. PET images were reconstructed by using different attenuation maps, and radioactivity concentrations were compared. The radioactivity concentration on germanium 68 (68Ge)-based corrected images was regarded as standard, and percentage bias, defined as difference divided by measured activity of 68Ge-based corrected images, was assessed. The relationship between the concentration of contrast agent and the percentage bias was assessed with the Pearson coefficient r, and the significance of correlations was evaluated with the Fisher z test. All phantom studies demonstrated that presence of a contrast agent resulted in overestimation of emission data. CT numbers showed a strong positive correlation with the percentage bias in phantoms 2 (r = 0.999) and 3 (r = 0.987); the maximum percentage bias at 1,360 HU reached approximately 45%. These effects were independent of FDG concentration. In a canine model, presence of a contrast agent also increased emission activity, but the percentage bias was less than 15% in the liver and smaller in all other organs except the kidney (26%). High concentrations of a contrast agent caused considerable overestimation of apparent tracer activity in phantom studies; however, the emission bias was relatively modest in vivo, except in areas with very high contrast agent concentrations.
The purpose of this study is to measure the organ doses and effective dose (ED) for parathyroid 4D CT and scintigraphy and to estimate the lifetime attributable risk of cancer incidence associated with imaging. Organ radiation doses for 4D CT and scintigraphy were measured on the basis of imaging with our institution's protocols. An anthropomorphic phantom with metal oxide semiconductor field effect transistor detectors was scanned to measure CT organ dose. Organ doses from the radionuclide were based on International Commission for Radiological Protection report 80. ED was calculated for 4D CT and scintigraphy and was used to estimate the lifetime attributable risk of cancer incidence for patients differing in age and sex with the approach established by the Biologic Effects of Ionizing Radiation VII report. A 55-year-old woman was selected as the standard patient according to the demographics of patients with primary hyperparathyroidism. Organs receiving the highest radiation dose from 4D CT were the thyroid (150.6 mGy) and salivary glands (137.8 mGy). For scintigraphy, the highest organ doses were to the colon (41.5 mGy), gallbladder (39.8 mGy), and kidneys (32.3 mGy). The ED was 28 mSv for 4D CT, compared with 12 mSv for scintigraphy. In the exposed standard patient, the lifetime attributable risk for cancer incidence was 193 cancers/100,000 patients for 4D CT and 68 cancers/100,000 patients for scintigraphy. Given a baseline lifetime incidence of cancer of 46,300 cancers/100,000 patients, imaging results in an increase in lifetime incidence of cancer over baseline of 0.52% for 4D CT and 0.19% for scintigraphy. The ED of 4D CT is more than double that of scintigraphy, but both studies cause negligible increases in lifetime risk of cancer. Clinicians should not allow concern for radiation-induced cancer to influence decisions regarding workup in older patients.